Individuals Stopping Weight-Loss Jabs Regain Weight at a Quadrupled Rate Compared to Dieters
New research indicates that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds far faster than those who stop conventional lifestyle plans.
Research printed in a leading medical journal shows that while obese people can lose about a fifth of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"Users using these treatments should be informed of the potential of fast rebound weight gain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment weight within about one and a half years.
Weighing Approaches
The research, which reviewed dozens of studies involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with other pills.
The team emphasize that people who shed pounds through lifestyle changes alone typically experience a less rapid creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Fast Rebound
Nutrition scientists propose the mechanism of the jabs is key to understanding the accelerated rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls hunger.
"Sustained high doses of the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication leads to hunger is uncontrolled, making overeating much more probable."
An Ongoing Disease?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, given the significant potential of weight regain, the treatment might need to be life-long.
This view is echoed by pharmaceutical companies, who say that the results "underscore the long-term character of excess weight," similar to managing diseases like diabetes.
Patient Experiences
People who have stopped the medication explain a sudden return of hunger.
"I experienced a trigger flipping and you're instantly ravenous," described one woman.
This difficulty is worsened if users have not developed sustainable dietary or behavioural changes during therapy.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have used these injections in the past year, with demand continuing to grow.
- Adoption is more common among females compared to males.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a standalone solution and long-term success relies on ongoing behavioural changes.